Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Long-term complications of Shiga toxin-producing Escherichia coli O157 (STEC O157) infection and STEC-associated haemolytic uraemic syndrome (STEC-HUS), Wales, 1990-2020

View through CrossRef
Abstract Background Information on sequelae of Shiga toxin-producing Escherichia coli (STEC) O157 infection is limited to short-term follow-up of paediatric haemolytic uraemic syndrome (HUS) cases. We investigate recorded long-term health outcomes experienced by individuals exposed to STEC O157 and STEC-HUS up to three decades on.Methods We compared acute or new onset of chronic outcomes in individuals ≥ 1 year after STEC O157 or STEC-HUS to unexposed general population comparators between 01/01/1990-01/01/2019. The unexposed were their age- and sex-equivalents (4:1 matching ratio) and assigned the same study entry date. Outcomes were identified in primary and secondary care and categorised as renal, neurological, cardiac, gastrointestinal, respiratory, or endocrine. Hazard ratios (HRs) and 95% confidence intervals (95%CI) were calculated using Cox regression.Results Of 1,245 individuals with STEC O157, 65 developed HUS (5.2%). Individuals with STEC O157 were more likely to experience renal (adjusted (a)HR: 1.9, 95%CI: 1.1–3.3), gastrointestinal (aHR: 1.7, 95%CI: 1.2–2.6) and respiratory (aHR: 1.3, 95%CI: 1.2–1.5) outcomes compared to the unexposed, on average between 3.4–11 years after exposure. Gastrointestinal (HR: 7.7, 95%CI: 2.6–23), renal (HR: 5.5, 95%CI: 1.6–19), cardiac (HR: 5.1, 95%CI: 1.1–23) and respiratory (HR: 1.9, 95%CI: 1.1–3.1) outcomes were more common in the STEC-HUS cohort and occurred sooner, on average after 2.7–4.8 years.Conclusions Long-term complications were nearly twice as likely in the STEC O157 cohort, and as many as eight times more likely following STEC-HUS. We recommend that those exposed to STEC be monitored for at least five years for late-emerging renal and extrarenal complications.
Title: Long-term complications of Shiga toxin-producing Escherichia coli O157 (STEC O157) infection and STEC-associated haemolytic uraemic syndrome (STEC-HUS), Wales, 1990-2020
Description:
Abstract Background Information on sequelae of Shiga toxin-producing Escherichia coli (STEC) O157 infection is limited to short-term follow-up of paediatric haemolytic uraemic syndrome (HUS) cases.
We investigate recorded long-term health outcomes experienced by individuals exposed to STEC O157 and STEC-HUS up to three decades on.
Methods We compared acute or new onset of chronic outcomes in individuals ≥ 1 year after STEC O157 or STEC-HUS to unexposed general population comparators between 01/01/1990-01/01/2019.
The unexposed were their age- and sex-equivalents (4:1 matching ratio) and assigned the same study entry date.
Outcomes were identified in primary and secondary care and categorised as renal, neurological, cardiac, gastrointestinal, respiratory, or endocrine.
Hazard ratios (HRs) and 95% confidence intervals (95%CI) were calculated using Cox regression.
Results Of 1,245 individuals with STEC O157, 65 developed HUS (5.
2%).
Individuals with STEC O157 were more likely to experience renal (adjusted (a)HR: 1.
9, 95%CI: 1.
1–3.
3), gastrointestinal (aHR: 1.
7, 95%CI: 1.
2–2.
6) and respiratory (aHR: 1.
3, 95%CI: 1.
2–1.
5) outcomes compared to the unexposed, on average between 3.
4–11 years after exposure.
Gastrointestinal (HR: 7.
7, 95%CI: 2.
6–23), renal (HR: 5.
5, 95%CI: 1.
6–19), cardiac (HR: 5.
1, 95%CI: 1.
1–23) and respiratory (HR: 1.
9, 95%CI: 1.
1–3.
1) outcomes were more common in the STEC-HUS cohort and occurred sooner, on average after 2.
7–4.
8 years.
Conclusions Long-term complications were nearly twice as likely in the STEC O157 cohort, and as many as eight times more likely following STEC-HUS.
We recommend that those exposed to STEC be monitored for at least five years for late-emerging renal and extrarenal complications.

Related Results

Hemolytic uremic syndrome caused by Shiga toxin–producing Escherichia coli in children: incidence, risk factors, and clinical outcome
Hemolytic uremic syndrome caused by Shiga toxin–producing Escherichia coli in children: incidence, risk factors, and clinical outcome
Abstract Background Hemolytic uremic syndrome (HUS) is a multisystemic disease. In a nationwide study, we characterized the incidence, clinical course, and prognosis of HUS caused ...
Virulence characteristics of Shiga toxin‐producing Escherichia coli from raw meats and clinical samples
Virulence characteristics of Shiga toxin‐producing Escherichia coli from raw meats and clinical samples
ABSTRACTShiga toxin producing Escherichia coli (STEC) are dangerous foodborne pathogens. Foods are considered as important sources for STEC infection in human. In this study, STEC ...
Prognosis and pathological characteristics of five children with non‐Shiga toxin‐mediated hemolytic uremic syndrome
Prognosis and pathological characteristics of five children with non‐Shiga toxin‐mediated hemolytic uremic syndrome
AbstractBackground: The three major signs of hemolytic uremic syndrome (HUS) are hemolytic anemia, thrombopenia and acute renal failure. HUS is classified into Shiga toxin‐mediate...
Shiga Toxin Therapeutics: Beyond Neutralization
Shiga Toxin Therapeutics: Beyond Neutralization
Ribotoxic Shiga toxins are the primary cause of hemolytic uremic syndrome (HUS) in patients infected with Shiga toxin-producing enterohemorrhagic Escherichia coli (STEC), a pathoge...
Enhancing detection of STEC in the meat industry: insights into virulence of priority STEC
Enhancing detection of STEC in the meat industry: insights into virulence of priority STEC
Detection of Shiga toxin-producing Escherichia coli (STEC) presenting high risk of human infections is challenging. In France, the latest Anses opinion categorized STEC in four gro...

Back to Top